120 related articles for article (PubMed ID: 27941281)
1. [Development of AML without karyotype abnormalities including the Ph chromosome in a CML patient on second-generation TKI therapy].
Sakai T; Konuma Y; Shimoyama S; Kohda K
Rinsho Ketsueki; 2016; 57(11):2329-2333. PubMed ID: 27941281
[TBL] [Abstract][Full Text] [Related]
2. Case Report of acute myeloid leukemia with "WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19" developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy.
Zhu H; Yang B; Liu J; Wu W; Ling Y
Medicine (Baltimore); 2020 Jan; 99(3):e18888. PubMed ID: 32011516
[TBL] [Abstract][Full Text] [Related]
3. Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.
Nakamura F; Arai H; Nannya Y; Ichikawa M; Furuichi S; Nagasawa F; Takahashi W; Handa T; Nakamura Y; Tanaka H; Nakamura Y; Sasaki K; Miyano S; Ogawa S; Mitani K
Int J Hematol; 2021 Jun; 113(6):936-940. PubMed ID: 33400143
[TBL] [Abstract][Full Text] [Related]
4. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
5. [Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment].
Fujii S; Miura I; Tanaka H
Rinsho Ketsueki; 2015 Jun; 56(6):681-6. PubMed ID: 26256879
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
[TBL] [Abstract][Full Text] [Related]
8. Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
Cheng J; Liao Y; Bin T; OUYang J; Chen S; Chen X; Zou W
Curr Med Res Opin; 2020 Nov; 36(11):1807-1812. PubMed ID: 32936052
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors.
Ni H; Sun X; Xu Y; Lyle D; Petersen P; Zhao X; Drum H; You B; Liu D; Liu C; Jiang JG
Cancer Genet; 2019 Oct; 238():44-49. PubMed ID: 31425925
[TBL] [Abstract][Full Text] [Related]
10. Primary Philadelphia chromosome positive acute myeloid leukemia: A case report.
Shao X; Chen D; Xu P; Peng M; Guan C; Xie P; Yuan C; Chen B
Medicine (Baltimore); 2018 Nov; 97(44):e12949. PubMed ID: 30383645
[TBL] [Abstract][Full Text] [Related]
11. [Clinical observation of chromosomal abnormalities in Ph negative cells of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors].
Wang J; Zhang Y; Zhou J; Zu YL; Li Z; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):412-6. PubMed ID: 27210877
[TBL] [Abstract][Full Text] [Related]
12. Transient presence of clonal chromosomal aberrations in Ph-negative cells in patients with chronic myeloid leukemia remaining in deep molecular response on tyrosine kinase inhibitor treatment.
Gniot M; Lewandowski K; Ratajczak B; Lewandowska M; Lehmann-Kopydłowska A; Jarmuż-Szymczak M; Komarnicki M
Cancer Genet; 2014; 207(10-12):503-10. PubMed ID: 25496750
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
14. [Clinical Analysis of Dasatinib and Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia].
Li Y; Wang BJ; Liu W; Liang ZY; Yin Y; Dong YJ; Wang Q; Sun YH; Xu WL; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):18-23. PubMed ID: 32027247
[TBL] [Abstract][Full Text] [Related]
15. [Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].
Yuan T; Wang XY; Lai YY; Qin YZ; Shi HX; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):547-553. PubMed ID: 32397016
[No Abstract] [Full Text] [Related]
16. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
17. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Groves MJ; Sales M; Baker L; Griffiths M; Pratt N; Tauro S
Cancer Genet; 2011 Jan; 204(1):39-44. PubMed ID: 21356190
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcome of Philadelphia Chromosome Positive Leukemia From Eastern Indian Subcontinent: An Experience in the Era of Tyrosine Kinase Inhibitor (TKI) Therapy.
Dey S; Bhattacharyya D; Gupta PP; Nath S
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e876-e885. PubMed ID: 34400115
[TBL] [Abstract][Full Text] [Related]
20. Gelatinous bone marrow transformation and emergence of clonal Philadelphia-negative cytogenetic abnormalities with excess blasts in a patient with chronic myeloid leukemia treated with dasatinib.
Hermel DJ; Nael A; Lu YT; Kim J; Brynes RK; Vergara-Lluri M; Akhtari M
Anticancer Drugs; 2019 Apr; 30(4):416-421. PubMed ID: 30875349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
